Based on the results of a comprehensive clinical and neurological examination of patients with MS and an epidemiological study using the registry data of the center of the RS of Volyn Regional Clinical Hospital (825 patients), the features of the disease in the Volyn region were studied. Higher number of sources of anthropogenic pollution, smaller area of forest plantations (r = -0.48, p <0.05), higher population density (r = 0.33, p <0.05), better provision by neuropathologists (r = 0.38, p <0,05) are common for districts with higher prevalence of MS. The average age of the onset of the disease is 30.14 ± 9.22 years. Among the Volyn patients 13,3% has RRMS, 56% - RPMS, 13,5% and 17,7% - SPMS and PPMS respectively. The RRMS is associated with an earlier onset of the disease, younger age of patients (p <0,05). The prevalence of MS is higher among women in all age groups, all districts. The gender rate is 1.9: 1. Gastrointestinal disease (gastro-esophageal reflux, stomach ulcer and duodenal ulcer, gastritis, duodenitis, dyspepsia), urolithiasis, radiculopathy, benign ovarian tumors, mammary gland diseases, ankylosing spondylitis are the most common comorbid diseases in patients with MS. The presence of comorbidity is associated with older age of the patient and the older age of onset of MS (p<0,05). The risk factors of MS in Volyn region are: anthropogenic pollution, month of ?birth, mother's origin from Volyn, older age of parents at the birth of the subject, the presence of two or more older sibs, shorter breastfeeding time of subject, shorter outdoor time, limited use of fruits, vegetables, berries, beef, cereals, the presence of chronic stress in life (p<0,05). The disease in childhood like chickenpox, rubella as well as H. pylori infection, DPT vaccination and BCG may have protective immune-regulating effects on the risk of the MS development (p <0,05). It has been proved that the average age, the age of the onset of the disease and the diagnosis in the lone and childless patients are younger (p <0.05). Based on the results of EDSS and MSFC (105 patients), it was found that the degree of progression of neurological deficits is combined with the elderly patient, the later onset of the disease and its diagnosis (p <0.05). It has been proved that there is a significant positive effect of immunomodifying therapy on the slowdown of the ?development of neurological deficiency after 1 year of observation
